Compare EH & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | SPRY |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.8M | 833.1M |
| IPO Year | 2019 | 2020 |
| Metric | EH | SPRY |
|---|---|---|
| Price | $11.00 | $8.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $21.85 | ★ $40.00 |
| AVG Volume (30 Days) | 641.5K | ★ 1.5M |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $33.23 | $90.76 |
| Revenue Next Year | $73.83 | $81.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.06 | $6.66 |
| 52 Week High | $20.44 | $18.63 |
| Indicator | EH | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 45.81 |
| Support Level | $9.06 | $8.05 |
| Resistance Level | $12.80 | $8.70 |
| Average True Range (ATR) | 0.52 | 0.54 |
| MACD | 0.16 | 0.07 |
| Stochastic Oscillator | 84.65 | 66.46 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.